Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Oncology
3
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
267%
Small Molecule
133%
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Celldex TherapeuticsHAMPTON, NJ
1 program1
Combination of varlilumab and nivolumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Secura BioDuvelisib
Celldex TherapeuticsCombination of varlilumab and nivolumab
Clinical Trials (2)
Total enrollment: 175 patients across 2 trials
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Start: Oct 2021Est. completion: Jun 2024
Phase 2Completed
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Start: Jan 2015Est. completion: Dec 2018175 patients
Phase 1/2Completed
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
11m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
11m ago
Office Administrator
SystImmune
11m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
22m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
25m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
25m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Monoclonal Antibody is the dominant modality (67% of programs)
3 companies competing in this space